Abstract
In the last decades the epidermal growth factor receptor (EGFR), which is frequently expressed in a variety of epithelial tumors, has been a major target of molecular anticancer therapy.
Keywords: EGFR, Monoclonal antibody, Tyrosine kinase inhibitor, resistance
Current Cancer Therapy Reviews
Title: Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors
Volume: 3 Issue: 4
Author(s): Floriana Morgillo, Giampaolo Tortora and Fortunato Ciardiello
Affiliation:
Keywords: EGFR, Monoclonal antibody, Tyrosine kinase inhibitor, resistance
Abstract: In the last decades the epidermal growth factor receptor (EGFR), which is frequently expressed in a variety of epithelial tumors, has been a major target of molecular anticancer therapy.
Export Options
About this article
Cite this article as:
Morgillo Floriana, Tortora Giampaolo and Ciardiello Fortunato, Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors, Current Cancer Therapy Reviews 2007; 3 (4) . https://dx.doi.org/10.2174/157339407782496988
DOI https://dx.doi.org/10.2174/157339407782496988 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design, Synthesis and Evaluation of Quinoline-based Small Molecule Inhibitor of STAT3
Letters in Drug Design & Discovery Oxidative Stress and Mitochondrial Dysfunction in Type 2 Diabetes
Current Pharmaceutical Design Cognitive, Psychological and Psychiatric Effects of Ionizing Radiation Exposure
Current Medicinal Chemistry The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment
Current Cancer Drug Targets Herpes Simplex Virus Vectors for the Nervous System
Current Gene Therapy Chemotherapy and Delivery in the Treatment of Primary Brain Tumors
Current Clinical Pharmacology mTOR Inhibition and the Tumor Vasculature
Current Angiogenesis (Discontinued) Oligonucleotides and G-quadruplex Stabilizers: Targeting Telomeres and Telomerase in Cancer Therapy
Current Pharmaceutical Design Physiology, Pharmacology and Pathophysiology of the pH Regulatory Transport Proteins NHE1 and NBCn1: Similarities, Differences, and Implications for Cancer Therapy
Current Pharmaceutical Design Nuclear Long Non-Coding RNAs as Epigenetic Regulators in Cancer
Current Medicinal Chemistry Second Generation Adeno-Associated Virus Type 2-based Gene Therapy Systems with the Potential for Preferential Integration into AAVS1
Current Gene Therapy Methylenetetrahydrofolate Reductase (MTHFR): A Novel Target for Cancer Therapy
Current Pharmaceutical Design Role of Pancreatic β-Cell Death and Cell Death-Associated Inflammation in Diabetes
Current Molecular Medicine Cellular Redox Modulator, ortho Mn(III) meso-tetrakis(N-n-Hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP5+ in the Treatment of Brain Tumors
Anti-Cancer Agents in Medicinal Chemistry cAMP-Mediated Regulation of CYP Enzymes and Its Application in Chemotherapy
Drug Metabolism Letters Basis for the Application of Analytical Models of the Bloch NMR Flow Equations for Functional Magnetic Resonance Imaging (fMRI): A Review
Recent Patents on Medical Imaging Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry It is All About Proteases: From Drug Delivery to In Vivo Imaging and Photomedicine
Current Medicinal Chemistry Pharmacological Modulation of Nitric Oxide Release: New Pharmacological Perspectives, Potential Benefits and Risks
Current Medicinal Chemistry Inventions Designed to Enhance Drug Delivery Across Epithelial and Endothelial Cells Through the Paracellular Pathway
Recent Patents on Drug Delivery & Formulation